Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)"
The article focuses on effective treatment of the novel coronavirus infection (COVID-19) at early stages and substantiates the requirement for antiviral therapy and for decreasing the viral load to prevent the infection progression. The absence of a specific antiviral therapy for the SARS-CoV-2 virus is stated. The authors analyzed results of early randomized studies using lopinavir/ritonavir, remdesivir, and favipiravir in COVID-19 and their potential for the treatment of novel coronavirus infection. Among the drugs blocking the virus entry into cells, the greatest attention was paid to the antimalaria drugs, chloroquine and hydroxychloroquine. The article addresses in detail ineffectiveness and potential danger of hydroxychloroquine, which demonstrated neither a decrease in the time of clinical recovery nor any improvement of prognosis for patients with COVID-19. The major objective was substantiating a possible use of bromhexine, a mucolytic and anticough drug, which can inhibit transmembrane serin protease 2 required for entry of the SARS-CoV-2 virus into cells. Spironolactone may have a similar feature. Due to its antiandrogenic effects, spironolactone can inhibit X-chromosome-related synthesis of ACE-2 receptors and activation of transmembrane serin protease 2. In addition to slowing the virus entry into cells, spironolactone decreases severity of fibrosis in different organs, including the lungs. The major part of the article addresses clinical examples of managing patients with COVID-19 at the University Clinic of the Medical Research and Educational Centre of the M. V. Lomonosov Moscow State University, including successful treatment with schemes containing bromhexine and spironolactone. In conclusion, the authors described the design of a randomized, prospective BISCUIT study performed at the University Clinic of the M. V. Lomonosov Moscow State University with an objective of evaluating the efficacy of this scheme.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Kardiologiia - 60(2020), 8 vom: 07. Sept., Seite 4-15 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Mareev, V Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 10.11.2020 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.18087/cardio.2020.8.n1307 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317240730 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317240730 | ||
| 003 | DE-627 | ||
| 005 | 20231225162828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.18087/cardio.2020.8.n1307 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1057.xml |
| 035 | |a (DE-627)NLM317240730 | ||
| 035 | |a (NLM)33155953 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Mareev, V Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)" |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.11.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The article focuses on effective treatment of the novel coronavirus infection (COVID-19) at early stages and substantiates the requirement for antiviral therapy and for decreasing the viral load to prevent the infection progression. The absence of a specific antiviral therapy for the SARS-CoV-2 virus is stated. The authors analyzed results of early randomized studies using lopinavir/ritonavir, remdesivir, and favipiravir in COVID-19 and their potential for the treatment of novel coronavirus infection. Among the drugs blocking the virus entry into cells, the greatest attention was paid to the antimalaria drugs, chloroquine and hydroxychloroquine. The article addresses in detail ineffectiveness and potential danger of hydroxychloroquine, which demonstrated neither a decrease in the time of clinical recovery nor any improvement of prognosis for patients with COVID-19. The major objective was substantiating a possible use of bromhexine, a mucolytic and anticough drug, which can inhibit transmembrane serin protease 2 required for entry of the SARS-CoV-2 virus into cells. Spironolactone may have a similar feature. Due to its antiandrogenic effects, spironolactone can inhibit X-chromosome-related synthesis of ACE-2 receptors and activation of transmembrane serin protease 2. In addition to slowing the virus entry into cells, spironolactone decreases severity of fibrosis in different organs, including the lungs. The major part of the article addresses clinical examples of managing patients with COVID-19 at the University Clinic of the Medical Research and Educational Centre of the M. V. Lomonosov Moscow State University, including successful treatment with schemes containing bromhexine and spironolactone. In conclusion, the authors described the design of a randomized, prospective BISCUIT study performed at the University Clinic of the M. V. Lomonosov Moscow State University with an objective of evaluating the efficacy of this scheme | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Spironolactone |2 NLM | |
| 650 | 7 | |a 27O7W4T232 |2 NLM | |
| 650 | 7 | |a Bromhexine |2 NLM | |
| 650 | 7 | |a Q1J152VB1P |2 NLM | |
| 700 | 1 | |a Orlova, Ya A |e verfasserin |4 aut | |
| 700 | 1 | |a Pavlikova, E P |e verfasserin |4 aut | |
| 700 | 1 | |a Matskeplishvili, S T |e verfasserin |4 aut | |
| 700 | 1 | |a Akopyan, Z A |e verfasserin |4 aut | |
| 700 | 1 | |a Plisyk, A G |e verfasserin |4 aut | |
| 700 | 1 | |a Seredenina, E M |e verfasserin |4 aut | |
| 700 | 1 | |a Asratyan, D A |e verfasserin |4 aut | |
| 700 | 1 | |a Potapenko, A V |e verfasserin |4 aut | |
| 700 | 1 | |a Malakhov, P S |e verfasserin |4 aut | |
| 700 | 1 | |a Samokhodskaya, L M |e verfasserin |4 aut | |
| 700 | 1 | |a Mershina, E A |e verfasserin |4 aut | |
| 700 | 1 | |a Sinitsyn, V E |e verfasserin |4 aut | |
| 700 | 1 | |a Bulanova, M M |e verfasserin |4 aut | |
| 700 | 1 | |a Fuks, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Mareev, Yu V |e verfasserin |4 aut | |
| 700 | 1 | |a Begrambekova, Yu L |e verfasserin |4 aut | |
| 700 | 1 | |a Kamalov, A A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kardiologiia |d 1961 |g 60(2020), 8 vom: 07. Sept., Seite 4-15 |w (DE-627)NLM000007153 |x 0022-9040 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2020 |g number:8 |g day:07 |g month:09 |g pages:4-15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18087/cardio.2020.8.n1307 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2020 |e 8 |b 07 |c 09 |h 4-15 | ||